MediWound is no longer a pure burn-care supply story. The equity now prices a late-stage chronic-wound option against a cash clock that is already running. The Phase III VALUE study of EscharEx, the bromelain-based debridement candidate for hard-to-heal ulcers, slipped its interim look and enrollment finish from year-end into the first quarter of next year after management said recruitment moved more slowly than planned. That delay does not kill the program, but it stretches the period in which the company funds a registrational trial before any readout. At the same time the commercial burn franchise gained a government channel through Vericel, the North American partner, after the Biomedical Advanced Research and Development Authority awarded Vericel a ten-year NexoBrid contract.
First-half revenue landed under $5 million. Full-year guidance still sits at $24 million to $26 million. That math puts almost the entire year on the second half, and management is leaning on a new Vericel master services agreement plus other government programs to close the gap. Cash and deposits stood at $36 million. That compared with $54 million at year-end. First-half burn totaled $20 million. The operating loss widened because VALUE spending stepped up, not because hospital demand for NexoBrid disappeared. The tension is whether a partnered, government-weighted second half can carry a Phase III that now runs longer than the January plan.
The August update reaffirmed the year guide and named the master services agreement as a second-half revenue contributor. It also pushed commercial supply from the expanded Yavne plant into the second half of next year, after the European Medicines Agency requested modifications following a pre-audit. Independent consultants now put the United States EscharEx opportunity above $1 billion once pressure ulcers enter the map. Does the next print prove the government channel is real, or does the cash clock force a raise before VALUE even finishes enrolling?